Clinical Utility of the Galactomannan Assay as a Screening Tool for Invasive Aspergillosis Following Allogeneic Hematopoietic Stem Cell Transplant  by Keating, T.M. et al.
S342 Poster Session IICare Alliance. Clinical information was obtained from the institu-
tional database.Multiple linear regressionwas used to analyze the pa-
tient and transplant characteristics that are associatedwith total costs.
Results:Median age was 50 years (range 21 to 69 years), and 62%
patients were male. Seventy eight percent transplants were for
acute leukemia/MDS. Reasons for second transplant were graft
failure (25%), relapse of original disease (65%) and other causes
e.g. secondary MDS/aplasia (10%). 73% of relapsed patients
were in remission at the time of the second transplant. Non-mye-
loablative conditioning was more common in the second allografts
(75%) than in first allografts (30%) and a higher proportion of sec-
ond allografts were from unrelated donors (76% vs. 43%). In the
first 100 days, relapse occurred in 25% patients and 64% experi-
enced $ grade II acute GVHD. Survival was 78% at 100 days
and 49% at one year after transplant. Regimen related toxicity ac-
counted for 75% of deaths within the first 100 days. The median
total cost in 2010 dollars was $137,600 ($4,500 - $434,200) for
the first 100 days, with approximately $135,600 (0 - $432,200)
for inpatient and $4,100 (0 - $17,200) for outpatient costs. The me-
dian length of hospital stay was 22 days (range 0 to 77 days). Mye-
loablative conditioning, unrelated donors and pulmonary
complications post-transplant were significant predictors of higher
costs for the second transplants.
Table 1. Predictors of costs for second allogeneic transplant
Variable Cost multiplier 95%CI p valuePre-transplant factors
Age<50 1
>50 0.89 0.53-1.47 0.64Disease
Acute leukemia/MDS 1
Lymphoma 0.65 0.28-1.48 0.31
Others 3.18 0.90-11.2 0.08Diseases status
Remission 1
Relapse 0.76 0.38-1.49 0.43Graft source
PBSC 1
BM 0.97 0.26-3.66 0.97
cord blood 0.83 0.35-1.94 0.67Conditioning
myeloablative 1
Non-myeloablative 0.45 0.23-0.86 0.02Year of transplant
Per year 0.88 0.73-1.06 0.18Reason for transplantTable 1. Guidelines for routine serum GM testing followingRelapse 1allogeneic HSCTGraft rejection 1.18 0.64-2.19 0.6
Others 1.48 0.45-4.95 0.52Patients undergoing myeloablative conditioning regimenDonor type
 Day 30-60 post transplant: weekly galactomannanRelated 1
 Day 60+ post transplant: weekly galactomannan for patients on$ 1 mg/kgUnrelated 2.39 1.34-4.25 0.006
steroids or ANC < 1000CMV serostatusNonmyeloablative conditioning regimennegative 1
 Day 30+: weekly galactomannan for patients on $ 1 mg/kg steroids orpositive 0.83 0.50-1.37 0.48
ANC < 1000Post-transplant complications
within 100 days
Death (n 5 12) 0.9 0.37-2.20 0.82
Relapse (n 5 14) 1.15 0.64-2.07 0.65
GVHD (II-IV) (n 5 35) 1.59 0.96-2.64 0.08
VOD (n 5 10)* 1.16 0.52-2.58 0.72
Pulmonary (n 5 5) 2.08 1.05-4.12 0.04
Renal (n 5 9) 1.58 0.59-4.18 0.37
Infection (n 5 29) 1.62 0.96-2.73 0.08*Veno-occlusive disease
Conclusion: Short-term costs of second transplants appear compa-
rable to those of first transplants especially since a majority of them
are non-myeloablative/reduced intensity regimens. Additional work
is neededwith larger numbers of patients to confirm these results and
identify additional characteristics that would predict the group with
the best clinical and economic outcomes.373
CLINICAL UTILITY OF THE GALACTOMANNAN ASSAY AS A SCREENING
TOOL FOR INVASIVE ASPERGILLOSIS FOLLOWING ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANT
Keating, T.M., Casper, C., Fredricks, D. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Background: Invasive aspergillosis (IA) can result in significant
morbidity for immunosuppressed patients, particularly after alloge-
neic hematopoietic stem cell transplant (HSCT). The serum galac-
tomannan (GM) assay has been utilized as a tool to facilitate early
detection of IA, however its clinical usefulness for screening has
not been well studied. Routine screening was performed at our cen-
ter for patients considered to be at highest risk of IA (Table 1) and
a review was conducted to determine whether this improved case
finding.
Methods: Clinical data, including demographics, transplant history
and GM testing was reviewed for all adult allogeneic transplant re-
cipients seen at our Center in 2008. Probable and proven cases of
IA were identified by chart review of patients with positive culture,
pathology, PCR or GM from serum, bronchoalveolar lavage, or
other clinical site and classified according to EORTC criteria for di-
agnosis of IA. AGMcut-off of$ 0.5 in a single sample defined a pos-
itive result.
Results: A total of 1,939 serum GM assays were performed in 2008
in 239 patients for a mean of 8.1 tests per patient. Six percent (n 5
117) of tests were positive in 49 patients. Of those, 20 patients
(41%) met the diagnosis of IA. The sensitivity of the GM assay in
this screening settingwas 31%with a specificity of 95%and a positive
predictive value of 25%.
There were 32 cases of IA identified in 2008. Thirteen (41%) of
the identified cases clearly met criteria for GM screening at our cen-
ter and only seven of these cases had a positive serum GM prior to
diagnosis. A positive serum GM led to diagnosis of IA in three pa-
tients. Other cases were identified during evaluation of respiratory
tract infection symptoms (n5 13), fever (n5 9), routine radiological
imaging (n5 5), or follow up of previously identified pulmonary dis-
ease (n 5 2).
Conclusions: The GM assay demonstrated poor sensitivity as
a screening tool in a population of adult patients following allogeneic
HSCT. Despite recommendations for routine screening in patients
at highest risk for IA, the galactomannan contributed to case finding
in only three of 32 identified cases. Most cases did not meet recom-
mendations for routine screening and did not have a positive GM
prior to diagnosis. GM has low value as a screening tool in HSCT
when employed using the guidelines described here.374
THE HEMATOPOIETIC CELL TRANSPLANTATION-SPECIFIC COMORBID-
ITY INDEX (HCT-CI) AND SURVIVAL FOLLOWING EXTRACORPOREAL
PHOTOPHERESIS, PENTOSTATIN, AND REDUCED DOSE TOTAL BODY IR-
RADIATION CONDITIONING
Hashmi, S., Oliva, J.L., Liesveld, J.L., Phillips, G.L., Nichols, D.,
Milner, L., Becker, M. University of Rochester, Rochester, NY
Background: The HCT-CI has been reported to be an informative
tool to predict survival after myeloablative and fludarabine-based re-
duced intensity conditioning SCT. Recipient age, disease type, dis-
ease status, and donor relatedness have also been associated with
survival. The specific aims of this study were to describe SCT recip-
ients who received photopheresis, pentostatin, and 2-6Gy total body
